Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NLS 2

Drug Profile

NLS 2

Alternative Names: NLS2

Latest Information Update: 07 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroLifeSciences
  • Developer NLS Pharmaceutics Ltd
  • Class Antianaemics; Heavy metals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder; Restless legs syndrome

Most Recent Events

  • 25 Sep 2020 No development reported - Phase-III for Attention-deficit hyperactivity disorder in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)
  • 25 Sep 2020 No development reported - Phase-III for Restless legs syndrome in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)
  • 19 Mar 2019 NLS Pharma Ltd, NLS-1 Pharma Ltd and NLS-0 Pharma merged to form NLS Pharmaceutics Ltd

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top